Introduction
We are an R&D-focused company that manufactures medical devices for diagnosing ophthalmic diseases such as dry eye based on the world's first goblet cell imaging technology developed by a research team at the nation's top university, and develops a comprehensive diagnostic platform that can diagnose various ophthalmic diseases and other diseases through image analysis using artificial intelligence (AI) technology.
TEAM
Former Nanophilia Executive Director
Former CJ Corporation Researcher
Former CJ Corporation Researcher
Director of Hean Seoul Eye Hospital
Former Professor of Ophthalmology at Asan Medical Center
Seoul National University Medical School Doctor of Medicine
Former Professor of Ophthalmology at Asan Medical Center
Seoul National University Medical School Doctor of Medicine
Professor, Department of Mechanical Engineering, POSTECH
Ph.D., MIT
Bachelor's degree, Seoul National University
Ph.D., MIT
Bachelor's degree, Seoul National University
Professor of Ophthalmology, Seoul National University Hospital
Doctor of Medicine, Seoul National University
Doctor of Medicine, Seoul National University
History
2015 ~
Research on technology based on visualization of alcohol glass tax table
Comparative analysis of performance of confocal and two-photon microscopes for corneal photography in experimental mice
2023~
Establishing an industry-academia cooperation system
Establishing an industry-academia cooperation system for efficient technology development (POSTECH-Seoul National University Hospital)
2023~
Samsung Future Technology Support Project Selection and Progress
2024~
Clinical trials underway
Clinical trials in progress to verify clinical performance
2024.10
Establishment of corporation
Establishment of a corporation for commercialization (Representatives: Kim Ki-yeon, Kim Myeong-jun)
2025.04
Corporate Research Institute Certification
Establishment of a corporation for commercialization (Respective representatives: Kim Ki-yeon, Kim Myeong-jun) Ministry of Science and ICT - Selected for the project to build a platform for regulatory support of bio-innovation technology